Company Overview

Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotechnology and biotechnology-adjacent healthcare company focused on developing treatments for central nervous system (CNS) disorders and advancing clinical and translational neuroscience initiatives. The company operates primarily in the biopharmaceutical industry, with an emphasis on psychiatric and neurological conditions, including treatment-resistant depression, post-traumatic stress disorder (PTSD), and other mental health disorders. Its business strategy combines therapeutic development with broader neuroscience-related clinical infrastructure and intellectual property initiatives.

The company’s primary value drivers have included drug development programs, clinical research capabilities, and strategic investments in emerging mental health treatment modalities. Pasithea has pursued opportunities connected to ketamine-related therapies, serotonergic compounds, and neuropsychiatric treatment technologies. Founded in 2020, the company evolved through a combination of biotechnology licensing activities, mental health clinic initiatives, and pharmaceutical development efforts. Public filings and investor disclosures indicate that the company has repositioned portions of its strategy over time toward proprietary therapeutic assets and clinical-stage development programs.

Business Operations

Pasithea Therapeutics generates value primarily through its biotechnology research and development activities. The company has historically organized operations around therapeutic development and mental health treatment infrastructure, including initiatives connected to anti-depressant and CNS-focused therapies. Its operations have included collaborations with academic and scientific institutions to support translational neuroscience research and preclinical development. The company’s pipeline activities have centered on compounds targeting neurological and psychiatric disorders, with emphasis on unmet clinical needs in mental health.

The company operates with a relatively lean corporate structure compared with larger pharmaceutical firms and has relied on licensing arrangements, external research partnerships, and contract research organizations to advance development programs. Internationally, Pasithea has maintained operational and strategic exposure through subsidiaries and affiliated activities in regions including the United States and United Kingdom. Public disclosures have referenced subsidiaries and operating entities associated with clinic development, biotechnology licensing, and therapeutic research initiatives, though the company’s operating footprint remains significantly smaller than large-cap biotechnology peers.

Strategic Position & Investments

Pasithea Therapeutics has positioned itself within the growing neuropsychiatric and mental health therapeutics sector, an area that has attracted increased investor and pharmaceutical industry attention due to rising demand for innovative CNS treatments. The company’s strategy has included pursuing intellectual property rights, licensing agreements, and development collaborations tied to novel psychiatric therapies and CNS drug candidates. Public company disclosures have also reflected efforts to expand its therapeutic pipeline through research partnerships and targeted investments in neuroscience-related technologies.

The company has evaluated opportunities in emerging treatment modalities involving psychedelic-inspired therapies, ketamine-associated treatment frameworks, and broader CNS-focused pharmaceutical development. Pasithea has also pursued strategic collaborations with scientific advisors and academic researchers to strengthen its translational medicine capabilities. While the company has announced development-stage initiatives and partnership activities, some operational details and long-term commercialization plans remain dependent on clinical progress, regulatory outcomes, and financing availability based on available public filings.

Geographic Footprint

Pasithea Therapeutics is headquartered in Miami Beach, Florida, and maintains operational exposure across multiple regions through research relationships, subsidiaries, and clinical initiatives. The company’s activities have primarily focused on the United States and United Kingdom, reflecting its historical involvement in mental health clinic development and biotechnology collaboration networks.

Its market presence remains concentrated in North America and parts of Europe rather than broad multinational commercial operations. Public filings and investor materials indicate that the company has pursued international scientific partnerships and exploratory expansion opportunities tied to neuroscience and psychiatric treatment markets. However, its commercial and operational scale remains limited relative to larger global biotechnology companies.

Leadership & Governance

Pasithea Therapeutics was co-founded by individuals with backgrounds in psychiatry, neuroscience, finance, and healthcare entrepreneurship. The company’s leadership has emphasized advancing innovative CNS therapies and supporting translational neuroscience research aimed at addressing unmet mental health needs. Governance and strategic oversight have been shaped through a combination of biotechnology executives, medical advisors, and capital markets professionals.

Key executives and leadership figures have included:

• Dr. Tiago Reis Marques – Co-Founder and Director
• Lawrence Steinman, MD – Co-Founder and Chairman
• Michael Kuchar – Chief Executive Officer
• Patrick Harverson – Executive Director
• Dr. Jose Almeida – Director and Scientific Leadership Contributor

Company leadership has consistently communicated a strategy centered on developing differentiated therapies for psychiatric and neurological disorders while leveraging scientific collaboration and clinical innovation. Public statements and corporate filings indicate a focus on disciplined capital allocation, pipeline advancement, and long-term participation in the evolving CNS therapeutics market.